Providing validated in vivo functional assays, electrophysiology and pharmacology expertise to strengthen NAMs, rare disease and ATMP consortia

We provide expertise in validated in vivo and advanced ex vivo tissue assays, combining electrophysiology, cellular signaling assays and pharmacology to study disease mechanisms and therapeutic responses. Our core strengths lie in ophthalmology and sensory neuroscience, with a focus on human-relevant, mechanism-based models suitable for New Approach Methodologies (NAMs).

We contribute quantitative functional readouts, mode-of-action studies and preclinical evaluation frameworks applicable to rare diseases and Advanced Therapy Medicinal Products (ATMPs), including cell- and gene-based approaches. Our work supports non-animal strategies, assay validation, standardisation and translational robustness, aligning with ERA objectives and regulatory-relevant biomedical research.

We are particularly interested in collaborative projects where functional phenotyping strengthens biological understanding, de-risks therapeutic development and accelerates translation within European research consortia.